Overview

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

Status:
Active, not recruiting
Trial end date:
2021-10-27
Target enrollment:
Participant gender:
Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb